Age-appropriate use of human papillomavirus vaccines in the U.S.

Gynecologic Oncology

Volumn 114, Issue 2, 2009, Pages 365-369

  Castle, Philip E ^a   Fetterman, Barbara ^b   Akhtar, Israh ^c   Husain, Mujtaba ^d   Gold, Michael A ^e   Guido, Richard ^f   Glass, Andrew G ^g   Kinney, Walter ^h  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Regional Laboratory   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g CENTER FOR HEALTH RESEARCH   (United States)

^h KAISER PERMANENTE   (United States)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Genital warts; HPV; Human papillomavirus (HPV); Vaccination

Indexed keywords

WART VIRUS VACCINE;

AGE DISTRIBUTION; CANCER GROWTH; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; CONDYLOMA ACUMINATUM; DRUG INDICATION; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION PREVENTION; PAPANICOLAOU TEST; PATIENT PARTICIPATION; PRIORITY JOURNAL; REVIEW; UNITED STATES; UTERINE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS CARCINOGENESIS; VIRUS INFECTION; WART VIRUS; WART VIRUS VACCINATION;

AGE FACTORS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS;

EID: 67649256053     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.04.035     Document Type: Review

References (37)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 1 (1999 Sep) 12-19
2. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. pidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348 6 (2003 Feb 6) 518-527
3. Schiffman M.H., Bauer H.M., Hoover R.N., Glass A.G., Cadell D.M., Rush B.B., et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 85 12 (1993 Jun 16) 958-964
4. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., and Wacholder S. Human papillomavirus and cervical cancer. Lancet 370 9590 (2007 Sep 8) 890-907
5. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121 3 (2007 Aug 1) 621-632
6. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356 19 (2007 May 10) 1928-1943
7. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl. J. Med. 356 19 (2007 May 10) 1915-1927
8. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007 Jun 30) 2161-2170
9. Kahn J.A., and Burk R.D. Papillomavirus vaccines in perspective. Lancet 369 9580 (2007 Jun 30) 2135-2137
10. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 7 (2007 Aug 15) 743-753
11. Wright Jr. T.C., and Bosch F.X. Is viral status needed before vaccination?. Vaccine 26 Suppl 1 (2008 Mar 14) A12-A15 A12-A15
12. Castle P.E., Solomon D., Saslow D., and Schiffman M. Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. Cancer 113 10 Suppl (2008 Nov 15) 3031-3035
13. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 2 (2008 Mar) 71-96
14. Castle P.E., Stoler M.H., Solomon D., and Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am. J. Clin. Pathol. 127 5 (2007 May) 805-815
15. Carreon J.D., Sherman M.E., Guillen D., Solomon D., Herrero R., Jeronimo J., et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int. J. Gynecol. Pathol. 26 4 (2007 Oct) 441-446
16. McCredie M.R., Sharples K.J., Paul C., Baranyai J., Medley G., Jones R.W., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 9 5 (2008 May) 425-434
17. Schiffman M., and Rodriguez A.C. Heterogeneity in CIN3 diagnosis. Lancet Oncol. 9 5 (2008 May) 404-406
18. Goldhaber-Fiebert J.D., Stout N.K., Salomon J.A., Kuntz K.M., and Goldie S.J. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J. Natl. Cancer Inst. 100 5 (2008 Mar 5) 308-320
19. Freeman H.P., and Wingrove B.K. Excess cervical cancer mortality: a marker for low access to health care in poor communities. National Institutes of Health (2007) Report No.: 05-5282
20. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., and Unger E.R. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 56 RR-2 (2007 Mar 23) 1-24
21. Saslow D., Castle P.E., Cox J.T., Davey D.D., Einstein M.H., Ferris D.G., et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J. Clin. 57 1 (2007 Jan) 7-28
22. Kjaer S.K., Tran T.N., Sparen P., Tryggvadottir L., Munk C., Dasbach E., et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J. Infect. Dis. 196 10 (2007 Nov 15) 1447-1454
23. Mosher W.D., Chandra A., and Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv. Data 362 (2005 Sep 15) 1-55
24. Castle P.E., Schiffman M., Herrero R., Hildesheim A., Rodriguez A.C., Bratti M.C., et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in guanacaste, costa rica. J. Infect. Dis. 191 11 (2005 Jun 1) 1808-1816
25. Saslow D., Runowicz C.D., Solomon D., Moscicki A.B., Smith R.A., Eyre H.J., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin. 52 6 (2002 Nov) 342-362
26. Munoz N., Hernandez-Suarez G., Mendez F., Molano M., Posso H., Moreno V., et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br. J. Cancer 100 7 (2009 Apr 7) 1184-1190
27. Plummer M., Schiffman M., Castle P.E., Maucort-Boulch D., and Wheeler C.M. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J. Infect. Dis. 195 11 (2007 Jun 1) 1582-1589
28. Trottier H., Mahmud S., Prado J.C., Sobrinho J.S., Costa M.C., Rohan T.E., et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J. Infect. Dis. 197 10 (2008 May 15) 1436-1447
29. Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., et al. Prevalence of HPV infection among females in the United States. JAMA 297 8 (2007 Feb 28) 813-819
30. Castle P.E., Fetterman B., Poitras N., Lorey T., Shaber R., and Kinney W. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet. Gynecol. 113 3 (2009 Mar) 595-600
31. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am. J. Obstet. Gynecol. 197 4 (2007 Oct) 346-355
32. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J. Low Genit. Tract. Dis. 11 4 (2007 Oct) 201-222
33. Wain G.V. "I want the one for older women" - extending the human papillomavirus vaccine population base. Med. J. Aust. 188 9 (2008 May 5) 501-502
34. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199 7 (2009 Apr 1) 926-935
35. Wheeler C.M., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Perez G., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J. Infect. Dis. 199 7 (2009 Apr 1) 936-944
36. Kim J.J., and Goldie S.J. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med. 359 8 (2008 Aug 21) 821-832
37. Kurman R.J., Henson D.E., Herbst A.L., Noller K.L., and Schiffman M.H. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 271 23 (1994 Jun 15) 1866-1869